FDA Approves Tavapadon: A New Treatment Option for Parkinson’s
A new treatment option for Parkinson’s disease (PD) just received approval. The US Food and Drug Administration (FDA) has approved JUVMO (tavapadon) for PD treatment in adults. The once-daily oral medication can be used either alone or alongside levodopa, providing another option for managing motor symptoms across different stages of the disease. The manufacturer of this new treatment option, AbbVie, expects it to be available to patients in the US next month (October 2026).
This is a huge milestone in PD treatment because it is the first approved selective D1/D5 dopamine receptor agonist for PD. This treatment offers a different approach to targeting the dopamine system, thereby providing another way to help control symptoms.
How Does Tavapadon Work?
PD progressively damages dopamine-producing neurons in the brain, which reduces the amount of dopamine available to regulate movement. This loss contributes to the movement symptoms seen in PD. Dopamine agonists work by activating dopamine receptors instead of physically replacing dopamine itself. The dopamine agonists that are currently available for use in the US include pramipexole, ropinirole, and rotigotine, and primarily target D2 and D3 dopamine receptors in the brain.
Tavapadon is different because it selectively activates D1 and D5 receptors as a partial agonist, potentially improving the side effect profile of dopamine agonists. Activation of the D2/D3 receptors drives sleepiness, impulse control disorders, and hallucinations and it is hypothesized that a dopamine agonist that activates D1/D5 receptors and not D2/D3 receptors would improve motor symptoms without inducing these side effects. Now that it has been approved and the medication will be used in real world situations, its side effect profile as compared to traditional dopamine agonists will become more evident.
What Did the Clinical Trials Show?
This FDA approval comes after the successful completion of AbbVie’s Phase 3 TEMPO clinical trial program, which evaluated tavapadon in people with PD motor symptoms taking levodopa and in early PD patients not taking levodopa.
In the previous TEMPO 1 and TEMPO 2 studies, tavapadon was found to significantly improve measures of motor function and activities of daily living compared with the placebo group after 26 weeks. It was also tested as an add-on treatment to levodopa in the TEMPO 3 trial to see how the two might complement each other.
At the 26-week mark, participants receiving tavapadon plus levodopa experienced an average of 1.7 more hours of daily “on” time without troublesome dyskinesia (a time when the medication is working well with reduced symptoms) compared to a 0.6-hour increase for those receiving the placebo plus levodopa. In contrast, the daily “off” time (a time when symptoms return) also decreased by 1.9 hours with tavapadon compared with 0.9 hours with placebo.
A longer-term follow up from the TEMPO 4 extension study also supported continued efficacy through 85 weeks.
What Does this Approval Mean?
Tavapadon offers a new treatment option for people with PD – both for those newly diagnosed who may need to start on a PD medication and for those already on levodopa. Managing symptoms and medication side effects in PD can be very challenging and having a new choice can offer hope to those who have not had successful management of their symptoms with the available options.
Tavapadon and its FDA approval means there is now a new way of targeting dopamine signaling that can be used with or without levodopa to best manage PD symptoms moving forward.